Genetic protection modifications: Moving beyond the binary distinction between therapy and enhancement for human genome editing
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Genetic protection modifications : Moving beyond the binary distinction between therapy and enhancement for human genome editing. / Mikkelsen, Rasmus Christen B; Frederiksen, Henriette Reventlow S.; Gjerris, Mickey; Holst, Bjørn; Hyttel, Poul; Luo, Yonglun; Freude, Kristine; Sandoe, Peter.
I: CRISPR Journal, Bind 2, Nr. 6, 2019, s. 362-369.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Genetic protection modifications
T2 - Moving beyond the binary distinction between therapy and enhancement for human genome editing
AU - Mikkelsen, Rasmus Christen B
AU - Frederiksen, Henriette Reventlow S.
AU - Gjerris, Mickey
AU - Holst, Bjørn
AU - Hyttel, Poul
AU - Luo, Yonglun
AU - Freude, Kristine
AU - Sandoe, Peter
PY - 2019
Y1 - 2019
N2 - The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities.
AB - The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities.
U2 - 10.1089/crispr.2019.0024
DO - 10.1089/crispr.2019.0024
M3 - Journal article
C2 - 31860350
VL - 2
SP - 362
EP - 369
JO - CRISPR Journal
JF - CRISPR Journal
SN - 2573-1599
IS - 6
ER -
ID: 233589263